Study In Airway Physiology In Children SERETIDE DISKUS ® Inhlaer and FLIXOTIDE® Inhaler Are Trademarks of GSK Group of Companies.

Phase 4

Completed

• Conditions: Asthma
• Interventions: Drug: Salmeterol/fluticasone propionate; Drug: Fluticasone propionate

• Registration Number: NCT00169546
• Lead Sponsor: GlaxoSmithKline

Brief Summary

Comparison of two asthma treatments by lung function measures.

Detailed Description

Not available

Study Timeline

• Study Start: 2003-01
• Study First Submitted: 2005-09-09
• Study First Submitted QC: 2005-09-12
• Study First Posted: 2005-09-15
• Primary Completion: 2005-12
• Study Completion: 2005-12
• Status Verified: 2016-09
• Last Update Submitted: 2016-09-13
• Last Update Posted: 2016-09-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 64

Inclusion Criteria

Not provided

Exclusion Criteria

• 3 or more courses of oral steroids in last 12 months.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Arm 1	Salmeterol/fluticasone propionate	-
Arm 1	Fluticasone propionate	-

Primary Outcome Measures

Name	Time	Method
sRAW (k.Pa.s) measured before the study medication dose at the end of treatment (week 6)

Secondary Outcome Measures

Name	Time	Method
sRAW measured pre-dose at Week 3. sRAW measured 48 hours after last study medication dose. % symptom-free days over Weeks 1-6. % symptom-free nights over Weeks 1-6. Type and frequency of adverse events.

Trial Locations

Locations (1)

GSK Investigational Site; 🇬🇧 Manchester, Lancashire, United Kingdom